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Human immunodefi   ciency virus/acquired immune-
  defi  ciency syndrome (HIV/AIDS) and tuberculosis (TB) 
are overlapping epidemics that cause an immense bur-
den of disease in sub-Saharan Africa. This region is home 
to the majority of the world’s co-infected patents, who 
have higher TB case fatality and recurrence rates than 
patients with TB alone. A World Health Organization 
interim policy has been developed to reduce the joint 
burden of TB-HIV disease, an important component of 
which is provision of HIV care to co-infected patients. 
This review focuses on HIV testing of TB patients and, 
for those who are HIV-positive, the administration of ad-
junctive cotrimoxazole preventive treatment (CPT) and 
antiretroviral treatment (ART). HIV testing has moved 
from a voluntary, client-initiated intervention to one that 
is provider-initiated and a routine part of the diagnostic 
work-up. The effi  cacy and safety of CPT in HIV-infected 
patients is now well established, and this is an essential 
part of the package of HIV care. ART scale-up in Africa 
can substantially improve outcomes in co-infected pa-
tients. However, the clinical and programmatic challenges 
of combining ART with anti-tuberculosis treatment need 
to be resolved to realise the full potential of this benefi  t. 
These include the optimal time to start ART, how best to 
combine rifampicin-containing regimens with fi  rst-line 
and second-line ART regimens, management of immune 
reconstitution disease, the role of isoniazid preventive 
treatment with ART after TB treatment completion, and 
where and how to provide combined treatment to best suit 
the patient. Clinical and operational studies in the next 
few years should help to resolve some of these issues.
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SUB-SAHARAN AFRICA bears the brunt of the over-
lapping epidemics of the human immunodefi  ciency 
virus (HIV) and tuberculosis (TB). Countries in south-
ern Africa are particularly affected, with over 50% of 
TB patients diagnosed each year being co-infected 
with HIV.1,2
HIV-TB co-infected patients treated only with stan-
dardised anti-tuberculosis chemotherapy have poor 
outcomes compared with patients who only have TB. 
Case fatality rates are higher,3 and in patients who 
complete treatment there is a higher rate of recurrent 
TB.4 Treatment outcomes are worse due to several 
factors: stigma leading to delays in seeking care and 
thus more advanced disease at the time of presenta-
tion to health services; diffi  culties in making an accu-
rate diagnosis of smear-negative TB;5 HIV-associated 
morbidity; drug-related side effects;6 and higher rates 
of nosocomially acquired drug-resistant TB,7 which in 
the routine setting takes too long to diagnose or may 
not be diagnosed at all.
The DOTS strategy on its own is inadequate for 
the optimal management of co-infected patients, and 
the TB-specifi  c Millennium Development Goals of 
reducing the prevalence and death rates of TB by 50% 
by 2015 will not be achieved in high HIV-burden areas 
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unless additional strategies and interventions are put 
in place. Under the leadership of the World Health 
Organization (WHO) and the Stop TB Partnership, 
TB-HIV guidelines,8 a TB-HIV strategic framework9 
and an interim TB-HIV policy (Table 1)10 have all been 
developed to reduce the burden of TB-HIV disease in 
severely affected countries. One of the main prongs of 
the TB-HIV interim policy is to reduce the impact of 
HIV in co-infected patients. This review will focus on 
three important interventions: provider-initiated HIV 
testing and counselling, cotrimoxazole preventive 
treatment (CPT) and antiretroviral treatment (ART).
THE IDEAL PACKAGE OF CARE FOR 
THE CO-INFECTED PATIENT
Once a patient is diagnosed with TB, HIV testing and 
counselling should be offered if the HIV status is un-
known or was previously reported as negative. If a 
patient previously tested HIV-positive, but there is no 
documented evidence, the test should be repeated, as 
in most African countries a patient can only access 
CPT and ART if there is proof of a positive HIV test 
result. Ideally, HIV testing is performed soon after the 
diagnosis of TB, before, during or just after the process 
of registration and start of anti-tuberculosis treat-
ment.11 If the patient is HIV-positive, he/she should 
be screened and treated for active opportunistic infec-
tions and offered CPT as soon as possible, provided 
there are no contraindications. The patient can then be 
considered for ART. The Figure highlights the main 
steps in providing HIV care to the co-infected patient.
HIV TESTING AND COUNSELLING OF 
TB PATIENTS
Voluntary counselling and HIV testing
The traditional approach to HIV testing, the only ap-
proach in vogue for many years, is voluntary counsel-
ling and testing (VCT). The decision is left entirely with 
the client or patient about whether to have the test, 
and the emphasis is on extensive pre-test counselling 
and the social and preventive implications of being 
HIV-infected or knowing one’s serostatus.12 This type 
of intervention has been shown in East Africa to pro-
mote behaviour change and reduce sexual transmis-
sion of HIV.13
Provider-initiated HIV testing
In 2002, De Cock and colleagues argued that HIV/
AIDS in Africa should be redefi  ned as a public health 
and infectious disease emergency and that there should 
be an increased focus on treatment, advocating for 
routine and diagnostic HIV testing within health care 
settings.14 This approach differs from VCT in that 
HIV testing is requested by the health care worker 
and is an integral part of the clinical interaction. There 
is greater emphasis on ‘opting out’ (patients undergo 
an HIV test as part of the diagnostic work-up unless 
they specifi  cally decline), and there is a higher prior-
ity on post-test rather than pre-test counselling, par-
ticularly if the patient is HIV-positive. Routine and 
diagnostic HIV testing is now usually promoted as 
‘provider-initiated’ (opt-out) testing.15
HIV testing for TB patients
HIV testing for TB patients is indicated for several 
reasons: 1) establishment of the diagnosis of HIV, 
2) a gateway to an adjunctive package of HIV clinical 
Figure   HIV care for the co-infected patient with tuberculosis. 
TB = tuberculosis; HIV = human immunodeﬁ  ciency virus.
Table 1  The WHO Interim Policy of reducing the joint burden 
of HIV and TB*
Prevent TB in people living with HIV
 •    TB infection control in health care and congregate settings
 •    Intensiﬁ  ed TB case ﬁ  nding
 •    Isoniazid preventive treatment
 •    Scale-up of antiretroviral treatment
Treat HIV in patients with TB
 •    HIV testing and counselling
 •    Cotrimoxazole preventive treatment
 •    Antiretroviral treatment
Establish collaboration between HIV and TB programmes
 •    Activities include setting up coordinating bodies at all levels, 
surveillance of HIV prevalence in TB patients, joint planning 
and resource mobilisation, training, supervision, monitoring 
and evaluation
* Adapted from reference 10.
WHO = World Health Organization; HIV = human immunodeﬁ  ciency virus; 
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treatment and care and 3) preventing onward trans-
mission of HIV. The latter may be achieved through 
disclosure of HIV status, HIV testing of partners, re-
ducing risky behaviours, making condoms readily 
available in TB services and clinics, screening and 
treating sexually transmitted infections and preventing 
unintended pregnancies and mother-to-child trans-
mission.16 In various reports, provider-initiated HIV 
testing for TB patients appears feasible and accept-
able and is associated with high rates of uptake.2,12,17 
From 2001 onwards, rapid HIV test kits were intro-
duced, replacing cumbersome HIV enzyme-linked im-
munosorbent assay (ELISA) tests, and these have fa-
cilitated the feasibility of and access to HIV testing for 
both provider and client.
Despite the obvious advantages of HIV testing, the 
routine uptake among TB patients has been slow. The 
Global Plan to Stop TB provides annual targets for TB-
HIV control, with particular attention being given to 
HIV testing of TB patients and enrolling HIV-positive 
patients on ART.18 In sub-Saharan Africa, by the end 
of 2006, 737 000 TB patients should have been HIV 
tested. Data for 2006 are not yet available, but at the 
end of 2005 only 17% of these 737  000 TB patients 
had been tested, suggesting that the target for 2006 
will not be met unless there is a signifi  cant improve-
ment in fi  eld activity. This may now be happening, 
with Malawi and South Africa (personal observations), 
Kenya, Rwanda and Zambia reporting large increases 
in the uptake of HIV testing by TB patients in 2006 
and 2007.2
Provision of HIV testing for all TB patients will re-
quire much better functioning health systems than is 
currently the case to ensure uninterrupted supplies of 
HIV test kits, adequate numbers and commitment of 
counsellors and TB care providers, and reliable and 
regular monitoring systems. Easier ways of embed-
ding HIV testing and counselling into the process of 
TB diagnosis or TB treatment registration should also 
be considered, with HIV testing performed before (for 
TB suspects) or at the point of TB diagnosis in wards 
or clinics or carried out as an essential and integral 
part of TB treatment registration.11 This approach, 
sensitively handled, might positively infl  uence patient 
and provider perception of ‘two diseases, one patient’ 
and facilitate better access to TB-HIV interventions.
COTRIMOXAZOLE PREVENTIVE TREATMENT 
FOR TB PATIENTS
Although there are no annual targets for CPT in the 
Global Plan to Stop TB, CPT is an integral part of the 
WHO TB-HIV interim policy and an important inter-
vention that, on its own, can save lives. Cotrimoxa-
zole (trimethoprim-sulphamethoxazole) is a widely 
available, cheap and safe antibiotic, which has a broad 
spectrum of activity against several HIV-related and 
non-HIV-related pathogens.19 In industrialised coun-
tries, it is widely used for primary and secondary pro-
phylaxis against Pneumocystis jirovecii pneumonia 
(PJP) and Toxoplasma gondii encephalitis.
In Africa, CPT was hardly considered until a ran-
domised controlled study from Cote d’Ivoire in 1999 
showed a 48% mortality reduction in HIV-positive TB 
patients given CPT compared with placebo.20 There 
were also signifi  cantly fewer hospital admissions due 
to septicaemia and enteritis. CPT was well tolerated, 
with only 1% of patients having skin reactions. A 
smaller study from South Africa, published shortly 
after the Cote d’Ivoire study, showed that CPT in HIV-
positive TB patients was associated with an increase 
in survival of approximately 60%.21 The Cote d’Ivoire 
study persuaded the WHO and the Joint United Na-
tions Programme for HIV/AIDS (UNAIDS) to issue 
provisional recommendations that CPT be given to 
all patients in Africa living with AIDS, including HIV-
positive patients with TB.22
Despite these recommendations, routine use of 
CPT in sub-Saharan Africa remained minimal due to: 
1) concerns about lack of effi  cacy in countries with 
already high rates of bacterial resistance to cotrimox-
azole (rates of resistance were low in Cote d’Ivoire at 
the time of the original study); 2) a possible upsurge 
in community rates of bacterial resistance to cotrimox-
azole; and 3) a possible increase in the resistance of 
malaria parasites to sulphadoxine-pyrimethamine (SP), 
which is still used as fi  rst-line treatment for malaria in 
several endemic countries. However, in the last few 
years, these concerns have been largely answered by 
clinical studies and trials.
Clinical studies and trials on CPT in Africa
In two rural districts in Malawi, a package of HIV 
testing, counselling and CPT as an adjunct to anti-
  tuberculosis treatment was associated with a 19% re-
duction in mortality compared with historical con-
trols, the number needed to treat to prevent one death 
in both district-based studies being 12 patients.17,23 In 
South Africa, where rates of dual TB-HIV infection 
were nearly 80%, CPT given to all TB patients, ir-
respective of HIV status, showed an overall mortality 
reduction of 29% compared with historical controls, 
the number needed to treat to prevent one death be-
ing 24 patients.24 Although not conducted solely in 
TB patients, a before-and-after-study in Uganda of 
CPT in HIV-positive individuals showed a 46% re-
duction in mortality, the number needed to treat to 
prevent one death being eight patients.25 Major bene-
fi  ts of CPT in Uganda were observed, although over 
three-quarters of isolated pathogens causing diar-
rhoea were resistant to cotrimoxazole. Signifi  cant 
benefi  ts from CPT were observed in patients whose 
CD4 cell counts were >500/mm3, leading to the con-
clusion that CPT is useful in all HIV-infected patients, 
irrespective of CD4 cell count. In Lusaka, Zambia, 
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and 80%, a randomised placebo-controlled trial in 
children showed that CPT was associated with a 43% 
reduction in mortality, with the reduction in mortality 
occurring across all ages and CD4 cell counts.26
There is an increase in bacterial resistance to cotri-
moxazole among TB patients taking CPT.27 However, 
a household study in Uganda provided reassuring evi-
dence that use of CPT among HIV-infected individu-
als did not lead to an increase in bacterial resistance 
to cotrimoxazole amongst family members.28 Although 
cotrimoxazole and SP have similar mechanisms of ac-
tion and resistance patterns, a randomised controlled 
study in Mali showed that CPT in children aged 5–
15 years was associated with excellent protective effi  -
cacy against malaria and did not select for SP-resistant 
parasites.29
Guidelines for use of CPT in HIV-infected patients, 
including those with TB
CPT therefore works even in areas with high rates of 
bacterial resistance. WHO guidelines endorse the 
use of CPT in HIV-infected adults and children in 
  resource-limited settings, and provide advice about 
dosages, contraindications, management of side ef-
fects and when to discontinue medication (Table 2).30 
In addition to reducing morbidity and mortality, CPT 
is a useful intervention for HIV-infected TB patients 
living in settings that have yet to access ART or whose 
CD4 cell counts are considered too high for initiation 
of ART. Furthermore, CPT could lay the foundation 
for medication adherence prior to ART.19 The future 
operational challenges are how to ensure uninterrupted 
provision of CPT to all co-infected patients and how 
to monitor usage and benefi  t.
Combining CPT with ART
There appears to be added benefi  t in combining CPT 
and ART. In HIV-infected adults in Uganda, CPT and 
ART together resulted in fewer malaria episodes com-
pared with using CPT alone.31 In Malawi, CPT started 
simultaneously with ART was associated with a 40% 
reduction in early 6-month mortality compared with 
using ART alone.32 In Cote d’Ivoire, a strategy of com-
bining CPT with ART resulted in signifi  cant gains in 
life expectancy, particularly if treatment was guided by 
CD4 cell counts.33 ART is given for life, but what about 
CPT? In industrialised countries, CPT would normally 
be stopped once ART has brought CD4-cell counts to 
above 200/mm3, at which levels PJP and T. gondii en-
cephalitis are rare. However, the same reasoning may 
not apply in Africa where rates of malaria, bacterial 
infections and diarrhoea are high and CPT provides a 
protective effect. Current WHO advice is that CPT, 
once started, should be given indefi  nitely if CD4 counts 
are not available for patient monitoring, but consid-
eration can be given to discontinuing CPT if follow-up 
CD4 counts rise above the threshold for starting CPT 
and provided adherence to ART has been good.30
One of the most commonly used fi  rst-line ART regi-
mens currently used in sub-Saharan Africa is a fi  xed-
dose combination of stavudine (d4T) + lamivudine 
(3TC) + nevirapine (NVP), with which CPT has no 
signifi  cant additive adverse reactions. However, due 
to d4T toxicity, the WHO is promoting more use of 
zidovudine (AZT), which is potentially haematotoxic, 
as is cotrimoxazole. Additive toxicity may therefore 
become an issue in the future.
ANTIRETROVIRAL TREATMENT FOR 
HIV-INFECTED TB PATIENTS
In 1995, ART transformed AIDS in the industrialised 
world from a fatal infectious disease into one that is 
potentially chronic and manageable.34 Despite addi-
tive adverse effects and paradoxical reactions, HIV-
infected TB patients in industrialised countries have 
greatly improved survival outcomes and excellent 
Table 2  Guidelines on use of cotrimoxazole preventive 
treatment
Policy recommendations
Adults CPT for all symptomatic HIV-positive adults 
(WHO Stages 2, 3 and 4)
CPT for HIV-positive adults with CD4 count of 
⩽500 cells/mm3 
Children CPT for all children born to HIV-positive mothers
CPT for all HIV-positive children aged <5 years, 
regardless of symptoms
CPT for all symptomatic HIV-positive children aged 
⩾5 years 
Dosages of cotrimoxazole
Adults 480 mg twice a day (1 tablet twice daily) or 960 mg 
once daily (1 double-strength tablet once daily)
Children Children aged 6–14 years: 480 mg once a day 
(1 tablet once daily)
Children aged 6 months—5 years: 240 mg once a 
day (1/2 tablet once daily)
Children aged 6 weeks—6 months: 125 mg once a 
day (1/4 tablet once daily)
Contraindications for CPT
Adults and
 children
Known allergy to cotrimoxazole or sulpha drugs
First trimester of pregnancy for pregnant women
Discontinuation of CPT
Adults Discontinue CPT in the event of severe cutaneous 
reactions, renal or hepatic disease or severe 
haematological toxicity
Children In HIV-exposed infants (i.e., children born to 
HIV-positive women), CPT should be taken 
until HIV infection can conﬁ  dently be excluded. 
At 18 months of age, and provided the child has 
stopped breast-feeding, the child should have an 
HIV test. If the child continues to breast-feed 
after 18 months, CPT is continued until 3 months 
after breast-feeding has stopped and the child is 
then offered an HIV test. In both situations, if 
the HIV test is positive, then the child continues 
on CPT. If the HIV test is negative, then the child 
discontinues CPT
Discontinue CPT in the event of severe cutaneous 
reactions, renal or hepatic disease or severe 
haematological toxicity
CPT = cotrimoxazole preventive treatment; HIV = human immunodeﬁ  ciency 
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virological responses to ART.35,36 In the last few years, 
African countries have been scaling up ART: by De-
cember 2006, an estimated 1  340  000 patients had 
been placed on ART in sub-Saharan Africa.37 HIV-
positive patients with TB are all potentially eligible 
for ART, because patients with pulmonary TB (and 
children with TB lymphadenitis) are classifi  ed in WHO 
Clinical Stage 3 and patients with extra-pulmonary 
TB in WHO Clinical Stage 4.38,39 There is thus every 
reason to expect that ART will reduce TB case fatality 
and recurrent TB in co-infected patients. 
The recommended anti-tuberculosis treatment reg-
imens for new patients with TB are shown in Table 3. 
In HIV-positive TB patients, the key tenets of anti-
  tuberculosis treatment are: 1) the need for daily rifam-
picin (RMP) during the initial phase; 2) the use of RMP, 
where possible, in the continuation phase (this leads 
to lower failure and relapse rates compared with isonia-
zid [INH] and ethambutol); and 3) a RMP-containing 
continuation phase that is given at least three times 
weekly (to prevent relapse and development of RMP 
resistance).40 The development of multidrug-resistant 
TB (MDR-TB) requires the use of a combination of a 
minimum of four effective drugs (Table 4).41 Combin-
ing anti-tuberculosis drugs with antiretroviral (ARV) 
drugs, both fi  rst- and second-line (Table 5),38,40 is not 
easy, and the diffi  culties encountered in the fi  eld have 
resulted in fewer patients than expected accessing 
ART. By the end of 2005, an estimated 25  000 HIV-
infected TB patients had been placed on ART against 
a 2006 target of 220 000.2 These diffi  culties have to be 
overcome, as the benefi  ts of combined treatment are 
substantial. In a comparatively well-resourced urban 
cohort in South Africa, with good adherence support, 
excellent immunological and virological outcomes are 
achievable under programme conditions.42 The issues 
around combined treatment are discussed below.
Timing of ART in co-infected patients who have 
started anti-tuberculosis treatment 
The optimal time to start ART in HIV-positive TB pa-
tients is an important but complicated issue, and there 
are arguments for early as well as delayed treatment 
Table 3  First-line anti-tuberculosis drugs and regimens for 
new patients*
Initial phase of treatment
(daily or 3 times a week)
Continuation phase 
of treatment
New patients
2EHRZ (SHRZ) 6HE
2EHRZ (SHRZ) 4HR
2EHRZ (SHRZ) 4H3R3
†
Previously treated patients (relapse, treatment
    after interruption, treatment failure)
2SEHRZ/1EHRZ 5HRE/5H3R3E3
†
* The number before a phase is the duration of that phase in months. An al-
ternative drug (or drugs) appears as a letter (or letters) in brackets.
† A number in subscript after a letter is the number of doses of that drug per 
week. If there is no number in subscript after a letter, then treatment with 
that drug is daily.
E = ethambutol; H = isoniazid; R = rifampicin; Z = pyrazinamide; S = strep-
tomycin.
Table 4  Second-line anti-tuberculosis drug regimens
A combination of
•   Any  ﬁ  rst-line drugs to which drug susceptibility is retained
•   A  ﬂ  uoroquinolone (oﬂ  oxacin or moxiﬂ  oxacin)
•   An injectable agent (capreomycin, kanamycin or amikacin)
•   Other second-line drugs, such as cycloserine, ethionamide or 
para-aminosalicylic acid
Table 5  Antiretroviral agents/regimens in common use in sub-Saharan Africa
A  Antiretroviral agents
Nucleoside reverse 
transcriptase inhibitors 
Nucleotide reverse 
transcriptase inhibitors
Non-nucleoside reverse 
transcriptase inhibitors
Protease 
inhibitors
Zidovudine (AZT)
Didanosine (ddI)
Lamivudine (3TC) 
Stavudine (d4T)
Abacavir (ABC)
Emtricitabine (FTC)
Tenofovir (TDF) Nevirapine (NVP)
Efavirenz (EFV)
Nelﬁ  navir (NFV) 
Saquinavir (SQV)
Ritonavir (RTV)
Lopinavir (LPV)
Indinavir (IDV)
Amprenavir (APV)
Tipranavir (TPV)
Atazanavir (ATV)
B  First- and second-line ART regimens
First-line regimens Stavudine + lamivudine + nevirapine
d4T 30 mg + 3TC 150 mg + NVP 200 mg (all twice a day)
Stavudine + lamivudine + efavirenz
d4T 30 mg + 3TC 150 mg (twice a day) + EFV 600 mg (once a day)
Zidovudine + lamivudine + nevirapine
AZT 300 mg + 3TC 150 mg + NVP 200 mg (all twice a day)
Zidovudine + lamivudine + efavirenz
AZT 300 mg + 3TC 150 mg (twice a day) + EFV 600 mg (once a day)
Second-line regimens Tenofovir + lamivudine (+ zidovudine) + lopinavir/ritonavir
TDF (once a day) + 3TC (AZT) (twice a day) + LPV/RTV (twice a day)
Didanosine + abacavir + lopinavir/ritonavir
ddI (once a day) + ABC (once or twice a day) + LPV/RTV (twice a day)HIV  care   for   co-infected   TB   patients   in   Africa  11
(Table 6). Current WHO guidelines provide recom-
mendations about when to start ART in relation to 
CD4 cell counts and when CD4 counts are unavail-
able (Table 7).38 In practice, when CD4 cell counts are 
unavailable, most patients have ART delayed until the 
continuation phase of anti-tuberculosis treatment. 
The problem with delayed initiation of ART is that 
many HIV-related TB deaths occur during the fi  rst 
2 months of anti-tuberculosis treatment,3 thus reduc-
ing the overall potential benefi  t of ART in reducing 
TB case fatality rates. In Malawi, where ART was pro-
vided to co-infected TB patients during the continua-
tion phase of anti-tuberculosis treatment (i.e., after 
2 months), ART had no signifi  cant impact in reducing 
case fatality.43 Over 60% of deaths occurred in the 
fi  rst 2 months of anti-tuberculosis treatment, before 
ART was started, and in the continuation phase death 
rates were not different between those on ART and 
those not on ART. These results are supported by South 
African data, which also favour much earlier initia-
tion of ART.44 In particular, patients whose CD4 cell 
counts are <100 cells/mm3 or who have WHO Stage 
4 disease have a very high mortality risk, and should 
probably commence ART as soon as possible within 
the 2–8 week timeframe of anti-tuberculosis treat-
ment, as recommended by the WHO.38
This presents clinical challenges, particularly in very 
under-resourced settings. In Malawi, for example, 
where ART was started in small numbers of co-infected 
patients in the second week of anti-tuberculosis treat-
ment, clinical management was diffi  cult and compli-
cated by adverse effects, immune reconstitution dis-
ease (IRD) or new illnesses.45 In contrast, in better 
resourced settings such as South Africa, early start of 
ART has not been overly problematic.42 The issue of 
when to start ART still needs further evaluation, but 
it is likely that the survival benefi  t that might come 
with early initiation of ART would outweigh the poorer 
eventual outcomes associated with delays in initiat-
ing ART.
Additive adverse effects
ARV drugs and anti-tuberculosis drugs may cause 
overlapping toxicity (Table 8). Additive drug toxicity 
compromises patient safety and is an important cause 
Table 6  Early vs. late ART for co-infected patients
Advantages Disadvantages
Start ART early: 2–8 weeks 
after start of anti-tuberculosis 
treatment during the initial 
phase
•   May reduce early TB-HIV morbidity and 
mortality, which is high in the ﬁ  rst 2 months 
of anti-tuberculosis treatment
•  May improve sputum smear conversion rates
•  May be an advantage in drug-resistant TB
•  High pill burden and poor drug adherence 
•  Additive toxicities due to more anti-tuberculosis 
drugs in initial phase 
• Rifampicin-nevirapine  interaction
•  Increased risk of immune reconstitution disease, 
especially if patient has a low CD4 count
Start ART later: 8 weeks after 
start of anti-tuberculosis
treatment during the 
continuation phase
•  Patient more stable
•  Pill burden less
•  Continuation phase may not have rifampicin, 
using isoniazid and ethambutol instead
•  Less risk of immune reconstitution disease
•  May have limited impact on TB case fatality because 
many HIV-infected TB patients who will die do so in 
the ﬁ  rst 2 months of   anti-tuberculosis treatment
•  Patients who get better on anti-tuberculosis 
treatment may not understand the additional need 
for ART, which might inﬂ  uence ART-seeking 
behaviour.
ART = antiretroviral treatment; TB = tuberculosis; HIV = human immunodeﬁ  ciency virus.
Table 7  World Health Organization recommendations about 
when to start ART in TB patients*
CD4 cell 
count / mm3
ART 
recommendations
Timing of ART in relation to 
start of TB treatment
<200 Recommend ART Between 2 and 8 weeks (in 
initial phase of TB treatment)†
200–350 Recommend ART After 8 weeks (in continuation 
phase of TB treatment)
>350 Defer ART Re-evaluate the patient at 
8 weeks and at the end of 
TB treatment
Not available Recommend ART Between 2 and 8 weeks
* Adapted from reference 38.
† As soon as possible within this time frame for those with the most advanced 
immune deﬁ  ciency.
ART = antiretroviral treatment; TB = tuberculosis.
Table 8  Additive adverse drug reactions between anti-
tuberculosis drugs and ART drugs
Adverse reaction
Main ARV
drug involved
Main
anti-tuberculosis
drug involved
Peripheral neuropathy (early or 
late side effect)
Stavudine Isoniazid
Cycloserine
Hepatitis (usually an early side 
effect. This is a major 
problem when combining 
rifampicin and second-line 
ritonavir-boosted protease 
inhibitor regimens)
Nevirapine Rifampicin
Isoniazid
Pyrazinamide
Gastrointestinal dysfunction, 
e.g., diarrhoea, abdominal 
pain (early or late side effect)
All All
Skin rash (usually early side 
effect)
Nevirapine Rifampicin
Isoniazid
Pyrazinamide
Cycloserine
Central nervous system 
dysfunction (early or late 
side effect)
Efavirenz Isoniazid
Cycloserine
Anaemia (usually early side 
effect)
Zidovudine Rifampicin
ART = antiretroviral treatment; ARV = antiretroviral.12  The   International   Journal   of   Tuberculosis   and   Lung   Disease
of discontinuation of ART and interruptions of TB 
and/or HIV treatment.
d4T used in standard dosages is a well-recognised 
cause of peripheral neuropathy, the risk increasing 
with concurrent use of INH.46 This can be partly pre-
vented or treated by ensuring that the patient also 
takes pyridoxine.
NVP is the non-nucleoside reverse transcriptase 
inhibitor (NNRTI) most likely to cause hepatotoxic-
ity and skin reactions, with the risk being increased in 
women with CD4 counts >250 cells/mm3, men with 
CD4 counts >400 cells/mm3 and patients with a body 
mass index of <18.5.47,48 Up to 10% of co-infected 
patients may have CD4 cell counts >350 cells/mm3 at 
the time of starting treatment,49 and, with the lack of 
access to CD4 count testing in many African settings, 
one in ten patients may be at increased risk of NVP-
induced toxicity. RMP, pyrazinamide and INH fur-
ther increase this risk.48 Rates of treatment-limiting 
toxicity are greater when combining NVP with RMP 
compared with combining efavirenz (EFV) with RMP,50 
and for this reason EFV is the preferred NNRTI in 
patients receiving anti-tuberculosis treatment.38
Pharmacokinetic interactions with ﬁ  rst-line 
ART regimens
NNRTIs are metabolised mainly through cytochrome 
P450 (CYP450) enzymes. The rifamycins (RMP, rifa-
pentine and rifabutin [RFB]) are potent inducers of 
this enzyme system, with RMP having the greatest ef-
fect and RFB the least, and they therefore cause re-
ductions in plasma concentrations of NNRTIs. RMP 
reduces the plasma concentrations of NVP by 30–40% 
and EFV by 20–25%,51,52 and there is concern that if 
drug levels are sub-therapeutic, this will lead to drug 
resistance and treatment failure.
There are various ways of dealing with this prob-
lem. First, the dose of NVP could be increased from 
200 mg to 300 mg twice daily:53 however, not only is 
this option diffi   cult to implement when fi  xed-dose 
combination regimens are used, but the risk of drug-
induced toxicity is also signifi  cantly increased. Second, 
EFV could be substituted for NVP. EFV is generally 
well tolerated, but the drug is potentially teratogenic 
(and at least half of treated patients are women), there 
is currently no fi  xed-dose generic combination with 
d4T and 3TC, and the drug is costly. There was de-
bate about whether the dose of EFV should be 600 mg 
or 800 mg daily. However, excellent virological out-
comes are achievable using the standard 600 mg dose 
of EFV,42,54 and this is what is now recommended in 
international guidelines.38,40 Third, RFB causes less 
reduction in levels of NNRTIs,55 and this could re-
place RMP. However, RFB is not available in fi  xed-
dose combinations, it has haematological side effects 
and it is currently too expensive. Finally, abacavir 
(ABC) and tenofovir (TDF) are NRTIs that can both 
be given with AZT and 3TC as triple or quadruple 
nucleoside/nucleotide regimens that have no clinically 
signifi   cant pharmacokinetic interaction with RMP. 
Although these triple/quadruple NRTI regimens are 
effective, they are largely untried in co-infected TB 
patients, there are concerns about their potency, ABC 
can cause life-threatening hypersensitivity and they are 
expensive.52
Despite their shortcomings, both NVP and EFV 
appear to have a broad therapeutic index and experi-
ence has shown that patients receiving standard dos-
ages concurrently with RMP have good clinical, im-
munological and virological outcomes.42,51,52 A small, 
but important point is that the lead-in phase of NVP 
(200 mg daily for the fi  rst 2 weeks) in the presence of 
RMP results in nearly 60% of plasma NVP levels be-
ing sub-therapeutic,45 and this practice should be 
avoided when RMP-based treatment is used, as viro-
logical outcomes have also been shown to be under-
mined.50 At present, EFV is the recommended NNRTI 
of fi  rst choice,38,40 but due to expense and a lack of 
suitable fi  xed-dose combinations, NVP will still be 
used concurrently with anti-tuberculosis treatment 
regimens until further evidence becomes available to 
suggest otherwise.
Pharmacokinetic interactions with second-line 
ART regimens
In the same way as NNRTIs, protease inhibitors (which 
are the cornerstone of second-line ART, Table 5) are 
metabolised through CYP450 enzymes. In addition, 
RMP increases the activity of the effl  ux multidrug 
transporter P-glycoprotein (P-gp), which contributes 
to the elimination of protease inhibitors. RMP reduces 
levels of unboosted protease inhibitors such as nel-
fi  navir, indinavir or atazanavir by more than 80%,40 
and these therefore cannot be used together. The prob-
lem can be overcome to some extent by using ritonavir 
(RTV) boosted protease inhibitors, although the doses 
of RTV required to produce therapeutic levels of pro-
tease inhibitors are typically much higher than are 
usually used. Several studies have investigated the use 
of lopinavir and saquinavir with high-dose RTV, but 
there is substantial interpatient variability, with some 
patients experiencing inadequate blood levels and 
some experiencing severe drug toxicity.40,56
RFB is an alternative to RMP that can be used with 
most protease inhibitors (with or without RTV boost-
ing), but, for the reasons discussed above, the use of 
RFB in Africa is at present almost non-existent. Until 
further data are available, if a fi  rst-line ART regimen has 
failed and the patient is on anti-tuberculosis treatment, 
clinicians may consider completing anti-tuberculosis 
treatment before switching to second-line ART. 
Immune reconstitution disease
It has long been recognised that anti-tuberculosis 
treatment in HIV-negative patients can be associated 
with a transient worsening of clinical disease a few 
days or weeks after initiation of treatment.57 However, 
the frequency of these reactions is greatly increased by HIV  care   for   co-infected   TB   patients   in   Africa  13
concurrent use of ART, and these demonstrate a 
strong temporal relationship with ART initiation. The 
pathogenesis of these IRD events is believed to be due 
to the restoration of cell-mediated immunity in re-
sponse to mycobacterial antigens.58 This increasingly 
recognised phenomenon causes diagnostic and man-
agement challenges (Table 9). IRD has been reported 
to occur in up to one third of TB patients initiating 
ART in high-income settings, and most commonly 
presents with fever, worsening respiratory manifesta-
tions and lymphadenopathy.58 However, reports from 
resource-poor countries to date have found lower rates 
of around 10%.59 In the only published study from 
sub-Saharan Africa, the timing of ART initiation was 
the over-riding determinant of risk: patients starting 
in the fi  rst month of anti-tuberculosis treatment had a 
70-fold greater adjusted risk of developing IRD com-
pared with patients starting ART beyond 3 months of 
treatment.60 Although some patients with TB-IRD die, 
the background mortality risk of these patients is also 
high, as they typically have very advanced immuno-
defi  ciency. Thus, in the study from South Africa,60 the 
development of TB-IRD was not associated with an ex-
cess mortality risk. As yet, there is no real evidence base 
for the management of TB-IRD and outcomes from 
randomised controlled trials are eagerly awaited.
Adjunctive treatment with isoniazid after completion 
of anti-tuberculosis treatment
In HIV-positive patients who have successfully com-
pleted anti-tuberculosis treatment, INH preventive 
treatment (secondary IPT) for 6–12 months effectively 
reduces the risk of recurrent TB.61,62 ART reduces the 
risk of developing TB in HIV-positive patients, and the 
magnitude of this benefi  t may increase over the fi  rst 
few years of treatment.63 Recent data from Brazil in 
HIV-infected clients who have not developed TB con-
fi  rm the benefi  t of ART and IPT on their own, but 
importantly show that ART and IPT together result in 
a highly signifi  cant 76% decline in risk of active TB.64 
Whether IPT courses should be repeated (as protec-
tive effi  cacy wanes with time) and whether post-TB 
treatment IPT confers any added advantage to long-
term ART are not known, and data are required from 
randomised controlled trials.
Where to provide anti-tuberculosis treatment
and ART
In many African countries, ART is delivered in hospi-
tal clinics, while anti-tuberculosis treatment is deliv-
ered in the continuation phase from health centres as 
a result of decentralised management over the last 5–
10 years.65 The logistic and fi  nancial diffi  culties that 
patients encounter in visiting health centres to collect 
anti-tuberculosis drugs and then hospitals to collect 
ART drugs are a major reason for the poor access of 
co-infected patients to ART. In countries with good 
TB-HIV programmes, fewer than a third of patients ac-
cess ART.2 Solutions include better geographical access 
to ART through expansion of clinics to rural areas;66 
consideration of ‘one-stop shops’, i.e., clinics where pa-
tients can receive both medications at the same time 
with either an ART clinic providing anti-tuberculosis 
treatment or a TB clinic providing ART;67 and more 
involvement of established community structures to 
deliver TB treatment and ART.
MDR-TB, XDR-TB and ART 
MDR-TB (defi  ned as resistance to at least INH and 
RMP) results from defi  ciencies in TB case management 
and programme control, and there is growing evi-
dence of an overlap between this epidemic and HIV.68 
This was dramatically illustrated by the report in 2006 
of a nosocomial outbreak of extensively drug-resistant 
TB (XDR-TB, caused by MDR strains also resistant 
to quinolones plus one of the injectable second-line 
agents) in KwaZulu Natal, South Africa.7 Mortality 
rates in patients co-infected with HIV and MDR- or 
XDR-TB are very high, even in specialised manage-
ment programmes.68 ART, perhaps given at an earlier 
stage in anti-tuberculosis treatment than is the case 
for drug-susceptible TB,51,52 should improve the prog-
nosis of HIV-related drug-resistant TB, although there 
are no data to confi  rm this. Second-line anti-tubercu-
losis drugs are associated with considerable adverse 
effects that overlap with those of ART drugs (Table 8), 
although the absence of RMP from the regimens does 
simplify the issue to some extent. Access to diagnostics 
for the early diagnosis of drug-resistant TB and the 
prevention of nosocomial/community-based transmis-
sion of drug-resistant TB among HIV-infected persons 
remain major challenges: these are topics too exten-
sive to be covered in this article.
CONCLUSION
TB-HIV co-infected patients have poor outcomes if 
just treated with DOTS regimens.69 The addition of 
provider-initiated HIV testing, CPT and ART should 
greatly improve prognosis. HIV testing and initiation 
Table 9  Immune reconstitution disease in TB patients starting 
ART
•  Clinical features often include fever, lymphadenopathy, 
worsening respiratory symptoms and signs
•  IRD usually occurs within 3 months after starting ART, but most 
commonly within the ﬁ  rst 4 weeks
•  Risk factors for TB-IRD include low baseline CD4 cell count, 
disseminated/extra-pulmonary TB, early initiation of ART and 
rapid immunological and virological responses to ART
•  Necessary to exclude other opportunistic infections and adverse 
effects of drugs before making the diagnosis of IRD
•  Symptoms and signs usually controlled by non-steroidal anti-
inﬂ  ammatory drugs or corticosteroids in more severe cases 
(corticosteroid dose adjusted for rifampicin interaction and 
tapered according to response)
•  ART should be continued unless severe or life-threatening IRD 
develops
TB = tuberculosis; ART = antiretroviral treatment; IRD = immune reconstitu-
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of CPT are straightforward, and what is now required 
of national programmes is the commitment and re-
sources to overcome the logistic hurdles of offering 
this package to all co-infected patients. Although ex-
cellent outcomes are achievable, the administration of 
ART to patients on anti-tuberculosis treatment is still 
fraught with management challenges. These need to be 
resolved through clinical and operational research if 
optimal benefi  t of ART is to be obtained. Future treat-
ment would be made considerably easier if there were 
wider availability of EFV in fi  xed-dose combinations, 
for example TDF, 3TC and EFV as a once daily fi  xed-
dose combination; cheaper generic fi  xed-dose formu-
lations of rifabutin for use with second-line protease 
inhibitor based regimens; replacement of d4T by TDF; 
and fi  nally, new and effective anti-tuberculosis drugs 
that have fewer interactions with ART. The introduc-
tion and scale-up of ART in sub-Saharan Africa has 
changed the environment in which we operate,70 and 
we should now make the most of this opportunity to 
reduce the suffering and death that has hitherto been 
caused by the twin epidemic of HIV and TB.
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Le virus de l’immunodéfi  cience humaine/syndrome de 
l’immunodéfi  cience acquise (VIH/SIDA) et la tubercu-
lose (TB) sont des épidémies qui se superposent et qui 
représentent un fardeau immense de maladie en Afrique 
sub-saharienne. Cette région est le site de la majorité des 
patients co-infectés au niveau mondial, chez lesquels la 
létalité par TB et le taux de rechute sont plus élevés par 
comparaison avec les patients atteints uniquement de 
TB. Une politique intérimaire de l’Organisation Mon-
diale de la Santé a été élaborée pour réduire le fardeau 
conjoint de la maladie VIH-TB, avec comme compo-
sante importante la fourniture de soins VIH aux patients 
co-infectés. Cette revue se concentre sur les tests VIH 
chez les patients TB et chez ceux qui sont séropositifs 
pour le VIH, sur l’administration conjointe d’un traite-
ment préventif au cotrimoxazole (CPT) et d’un traite-
ment antirétroviral (ART). Les tests VIH sont passés 
d’une intervention volontaire initiée par les patients à 
une intervention initiée par le pourvoyeur de soins 
comme élément du travail de diagnostic de routine. Il est 
bien établi aujourd’hui que la CPT chez les patients in-
fectés par le VIH est effi  cace et sûre et qu’elle constitue 
une part essentielle de l’ensemble des soins VIH. L’exten-
sion de l’ART en Afrique peut améliorer de manière 
substantielle les résultats chez les patients co-infectés. 
Toutefois, il faut résoudre les défi  s cliniques et program-
matiques de la combinaison de l’ART avec le traitement 
antituberculeux pour atteindre le potentiel maximal de 
cette amélioration. Ces éléments comportent le moment 
optimal du début de l’ART, la meilleure façon de combi-
ner les régimes à base de rifampicine avec les régimes de 
première et de deuxième ligne de l’ART, la prise en 
charge de la maladie de reconstitution immunitaire, le 
rôle de la chimioprévention à l’isoniazide en combinai-
son avec l’ART après l’achèvement du traitement de la 
TB ainsi que le lieu et la façon de fournir un traitement 
conjoint pour répondre au mieux aux convenances du 
patient. Des études cliniques et opérationnelles à conduire 
dans les quelques prochaines années devraient aider à 
résoudre certains de ces problèmes.
RÉSUMÉ
RESUMEN
La infección por el virus de la inmunodefi  ciencia hu-
mana y el síndrome de inmunodefi  ciencia  adquirida 
(VIH/SIDA) y la tuberculosis (TB) provocan epidemias 
superpuestas que dan origen a una carga de morbilidad 
considerable en África subsahariana. En esta región ha-
bita la mayor cantidad de personas coinfectadas y presen-
tan una mortalidad por TB y tasas de recaídas más altas 
que los pacientes que padecen exclusivamente la TB. La 
Organización Mundial de la Salud elaboró una política 
interina con el propósito de reducir la carga de morbili-
dad conjunta de la infección por el VIH y la TB, uno de 
cuyos principales componentes es la provisión de cuida-
dos de la infección por el VIH a pacientes coinfectados. 
El presente estudio analiza en primer lugar la realización 
de la prueba diagnóstica de infección por el VIH en pa-
cientes tuberculosos y el suministro de tratamiento pre-
ventivo con cotrimoxazol (CPT) y de tratamiento anti-
retrovírico (ART). Se evolucionó de la política de prueba 
serológica del VIH voluntaria por iniciativa del usuario, 
a la prueba por iniciativa del proveedor de atención de 
salud y a la prueba como parte del estudio sistemático. 
Actualmente, se encuentran bien establecidas la efi  cacia 
y la seguridad toxicológica del CPT en pacientes in-
fectados por el VIH, y este constituye una parte esencial 
del cui  dado de la infección por el virus. La expansión del 
ART en África puede mejorar en forma considerable el 
desenlace clínico de los pacientes coinfectados. Sin em-
bargo, existen difi  cultades clínicas y programáticas en 
la asociación del ART y el tratamiento antituberculoso, 
que deben resolverse a fi  n de obtener todo el benefi  cio 
posible de esta medida. Entre los problemas se encuen-
tran defi  nir el momento óptimo para comenzar el ART, 
la mejor manera de asociar las pautas con rifampicina y 
los ART de primera y segunda línea, el tratamiento del 
síndrome de reconstitución inmune, la utilidad de la pro-
fi  laxis con isoniacida con el ART tras la compleción del 
tratamiento antituberculoso y dónde y cómo proveer el 
tratamiento combinado que se acomode mejor a las ne-
cesidades del paciente. La realización de estudios clínicos 
y operativos en los próximos años debería ayudar a re-
solver algunas de estas difi  cultades.